Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in Refractory Stage IV ENKTCL
NCT03618238Phase 2Completed
- Sponsor
- Xinhua Hospital
- Start
- Jul 2018
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Xinhua Hospital. Primary endpoint: Overall Response Rate at 12 weeks. Started Jul 2018; status: completed.
02
Drugs
anlotinib
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT03618238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03618238.